Skip to main content
Log in

Abstract

Evidence to support the contention that estrogen biosynthesis in breast cancers is of clinical significance has been sought by relating activity to (i) clinical response to aromatase inhibitors and (ii) tumor concentrations of estrogens. Significant correlations have been reported between the presence/high levels of tumor aromatase in vitro and likelihood of response to aminoglutethimide in patients with advanced breast cancer, but the association is not absolute and it has been more difficult to demonstrate similar relationships in patients with earlier stages of cancers treated with other more potent inhibitors. There are however data to suggest that in vitro measurements of aromatase may not reflect in situ estrogen synthesis. For example mammary adipose tissue fibroblasts preincubated with reversible aromatase inhibitors may paradoxically display elevated in vitro aromatase activity. Similar enhanced in vitro activity may be observed in breast material taken from patients treated neo-adjuvantly with aromatase inhibitors such as aminoglutethamide and letrozole. That this is an artifact of in vitro systems can be demonstrated by performing in situ assessments of aromatase activity in patients before and after treatment with aromatase inhibitors. Thus it can be shown that letrozole markedly inhibits in situ aromatase and reduces tumor levels of estrogens.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Miller WR: Aromatase activity in breast tissue. J Steroid Biochem Mol Biol 39: 783–790, 1991

    Article  PubMed  CAS  Google Scholar 

  2. Abul-Hajj YJ, Iverson R, Kiang DT: Aromatization of androgens by human breast cancer. Steroids 33: 205–222, 1979

    Article  PubMed  CAS  Google Scholar 

  3. Miller WR, Anderson TJ, Jack WJL: Relationship between tumour aromatase activity, tumour characteristics and response to therapy. J Steroid Biochem Mol Biol 37: 1055–1059, 1990

    Article  PubMed  CAS  Google Scholar 

  4. Bezwoda WR, Mansoor N, Dansey R: Correlation of breast tumour aromatase activity and response to aromatase inhibition with aminoglutethimide. Oncology 44: 345–349, 1987

    Article  PubMed  CAS  Google Scholar 

  5. Miller WR, O'Neill J: The importance of local synthesis of estrogen within the breast. Steroids 50: 537–538, 1987

    Article  PubMed  CAS  Google Scholar 

  6. Miller WR, Anderson EC: The biological relevance of aromatase activity in breast tumours. In: Robustelli G, Della Cuna, Manni A, Pannutti F (eds) Clinical Use of Aromatase Inhibitors. Current Data and Future Perspectives. Edizioni Medico Scientifiche — Pavia, 1995, pp 89–93

  7. Santen RJ, Santner S, Davis B, Veldhuis J, Smojlik E, Ruby E: Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab 47: 1257–1265, 1978

    Article  PubMed  CAS  Google Scholar 

  8. Murray FT, Santner S, Samojlik E, Santen RJ: Serum aminoglutethimide levels: studies of serum half-life clearance and patient compliance. J Clin Pharmacol 19: 704–711, 1979

    PubMed  CAS  Google Scholar 

  9. Foidart A, Harada N, Balthazart J: Effects of steroidal and non steroidal aromatase inhibitors on sexual behaviour and aromatase-immunoreactive cells and fibers in the quail brain. Brain Res 657: 105–123, 1994

    Article  PubMed  CAS  Google Scholar 

  10. Miller WR, Mullen P: Factors influencing aromatase activity in the breast. J Steroid Biochem Mol Biol 44: 597–604, 1993

    Article  PubMed  CAS  Google Scholar 

  11. Lonning PE: Pharmacology of new aromatase inhibitors. The Breast 5: 202–208, 1996

    Article  Google Scholar 

  12. Reed MJ, Aherne GW, Ghilchik MW, Patel S, Chakraborty J: Concentrations of oestrone and 4-hydroxyandrostenedione in malignant and normal breast tissues. Int J Cancer 49: 562–565, 1991

    PubMed  CAS  Google Scholar 

  13. van Landeghem AAJ, Poortman J, Nabuurs M, Thijssen JH: Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res 45: 2900–2906, 1985

    PubMed  CAS  Google Scholar 

  14. Vermeulen A, Deslypere JP, Paridaens R, Leclercq G, Roy F, Heuson JC: Aromatase 17β hydroxy-steroid dehydrogenase and intratissular sex hormone concentration in cancerous and normal glandular breast tissue in postmenopausal women. Eur J Cancer Clin Oncol 22: 515–525, 1986

    Article  PubMed  CAS  Google Scholar 

  15. Vermeulen A: Human mammary cancer as a site of sex steroid metabolism. Cancer Surveys 5: 585–595, 1986

    PubMed  CAS  Google Scholar 

  16. Thijssen JHH, Blankenstein MA, Donker GH, Daroszewski J: Endogenous steroid hormones and local aromatase activity in the breast. J Steroid Biochem 39: 799–804, 1991

    Article  CAS  Google Scholar 

  17. Miller WR, O'Neill JS: The relevance of local oestrogen metabolism within the breast. Proc Royal Soc Edinburgh 95B: 203–217, 1989

    Google Scholar 

  18. Miller WR: Uptake and synthesis of steroid hormones by the breast. Endocrine Related Cancer 4: 307–311, 1997

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miller, W., Mullen, P., Telford, J. et al. Clinical importance of intratumoral aromatase. Breast Cancer Res Treat 49 (Suppl 1), S27–S32 (1998). https://doi.org/10.1023/A:1006036419833

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006036419833

Navigation